Skip to main content
Journal cover image

Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY.

Publication ,  Journal Article
Wang, H; Estrella, JS; Chatterjee, D; Katz, MH; Rashid, A; Wolff, RA; Varadhachary, GR; Lee, JE; Pisters, PW; Abbruzzese, JL; Fleming, JB
Published in: Pathology
October 2014

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies with less than 5% five-year survival rate. Despite significant improvements in medical and surgical oncology and postoperative mortality rate, the overall survival for patients with pancreatic cancer has not changed significantly in the last four decades. Neoadjuvant chemoradiation therapy (NCT) is increasingly used to treat patients with potentially resectable PDAC, especially for patients with borderline resectable disease. However, analysis of prognostic factors is limited for patients with PDAC treated with NCT and pancreaticoduodenectomy. We systemically examined the pancreaticoduodenectomy specimens from 240 consecutive patients with PDAC who received NCT and pancreaticoduodenectomy between 1999 and 2007 at our institution. We found that posttreatment pathologic stage, pathologic tumor response grading, tumor involvement of the superior mesenteric/portal vein, tumor invasion into the muscular vessels, and perineural invasion are significant prognostic factors in our patient population. Therefore careful pathologic evaluation of the pancreatectomy specimens plays a key role in predicting prognosis of patients with PDAC who received NCT and pancreaticoduodenectomy.

Duke Scholars

Published In

Pathology

DOI

EISSN

1465-3931

Publication Date

October 2014

Volume

46 Suppl 2

Start / End Page

S25

Location

England

Related Subject Headings

  • Pathology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, H., Estrella, J. S., Chatterjee, D., Katz, M. H., Rashid, A., Wolff, R. A., … Fleming, J. B. (2014). Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY. Pathology, 46 Suppl 2, S25. https://doi.org/10.1097/01.PAT.0000454135.19954.47
Wang, H., J. S. Estrella, D. Chatterjee, M. H. Katz, A. Rashid, R. A. Wolff, G. R. Varadhachary, et al. “Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY.Pathology 46 Suppl 2 (October 2014): S25. https://doi.org/10.1097/01.PAT.0000454135.19954.47.
Wang H, Estrella JS, Chatterjee D, Katz MH, Rashid A, Wolff RA, et al. Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY. Pathology. 2014 Oct;46 Suppl 2:S25.
Wang, H., et al. “Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY.Pathology, vol. 46 Suppl 2, Oct. 2014, p. S25. Pubmed, doi:10.1097/01.PAT.0000454135.19954.47.
Wang H, Estrella JS, Chatterjee D, Katz MH, Rashid A, Wolff RA, Varadhachary GR, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB. Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY. Pathology. 2014 Oct;46 Suppl 2:S25.
Journal cover image

Published In

Pathology

DOI

EISSN

1465-3931

Publication Date

October 2014

Volume

46 Suppl 2

Start / End Page

S25

Location

England

Related Subject Headings

  • Pathology
  • 1103 Clinical Sciences